Clinical and laboratory characteristics of 182 patients with PMF stratified by the presence or absence of adverse sequence variants/mutations
| Characteristic . | Patients . | P . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| All (n = 182) . | With adverse variants (n = 102; 56%) . | Without adverse variants (n =80; 44%) . | ||||||||
| No. . | % . | Median (range) . | No. . | % . | Median (range) . | No. . | % . | Median (range) . | ||
| Age, years | 63 (22-87) | 65 (37-84) | 61 (22-87) | .005 | ||||||
| Male sex | 118 | 65 | 71 | 70 | 47 | 59 | .13 | |||
| Hemoglobin, g/dL | 10.1 (5.8-16) | 10 (5.8-15.3) | 10.8 (6-16) | .05 | ||||||
| Leukocytes × 109/L | 10.5 (1.9-219) | 10 (2-219) | 10.7 (1.9-115.1) | .84 | ||||||
| Platelets × 109/L | 224 (11-1493) | 202 (11-692) | 263 (13-1493) | .03 | ||||||
| DIPSS-plus risk category | .002 | |||||||||
| Low | 25 | 14 | 9 | 9 | 16 | 20 | ||||
| Intermediate-1 | 30 | 17 | 12 | 12 | 18 | 22 | ||||
| Intermediate-2 | 70 | 38 | 39 | 38 | 31 | 39 | ||||
| High | 57 | 31 | 42 | 41 | 15 | 19 | ||||
| Karyotype | .54 | |||||||||
| Normal | 105/179 | 59 | 59/99 | 60 | 46/80 | 58 | ||||
| Unfavorable | 22/179 | 12 | 14/99 | 14 | 8/80 | 10 | ||||
| Driver mutation distribution | .26 | |||||||||
| JAK2 | 109 | 60 | 66 | 65 | 43 | 54 | ||||
| CALR | 40 | 22 | 17 | 17 | 23 | 29 | ||||
| MPL | 11 | 6 | 6 | 6 | 5 | 6 | ||||
| Triple-negative | 22 | 12 | 13 | 13 | 9 | 11 | ||||
| No. of variants/mutations other than JAK2/CALR/MPL | <.001 | |||||||||
| 0 | 35 | 19 | 0 | 0 | 35 | 44 | ||||
| 1 | 64 | 35 | 30 | 30 | 34 | 43 | ||||
| 2 | 48 | 26 | 39 | 39 | 9 | 11 | ||||
| 3 | 18 | 10 | 17 | 17 | 1 | 1 | ||||
| 4 | 10 | 6 | 9 | 9 | 1 | 1 | ||||
| 5 | 3 | 2 | 3 | 3 | 0 | 0 | ||||
| 6 | 3 | 2 | 3 | 3 | 0 | 0 | ||||
| 11 | 1 | <1 | 1 | 1 | 0 | 0 | ||||
| Characteristic . | Patients . | P . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| All (n = 182) . | With adverse variants (n = 102; 56%) . | Without adverse variants (n =80; 44%) . | ||||||||
| No. . | % . | Median (range) . | No. . | % . | Median (range) . | No. . | % . | Median (range) . | ||
| Age, years | 63 (22-87) | 65 (37-84) | 61 (22-87) | .005 | ||||||
| Male sex | 118 | 65 | 71 | 70 | 47 | 59 | .13 | |||
| Hemoglobin, g/dL | 10.1 (5.8-16) | 10 (5.8-15.3) | 10.8 (6-16) | .05 | ||||||
| Leukocytes × 109/L | 10.5 (1.9-219) | 10 (2-219) | 10.7 (1.9-115.1) | .84 | ||||||
| Platelets × 109/L | 224 (11-1493) | 202 (11-692) | 263 (13-1493) | .03 | ||||||
| DIPSS-plus risk category | .002 | |||||||||
| Low | 25 | 14 | 9 | 9 | 16 | 20 | ||||
| Intermediate-1 | 30 | 17 | 12 | 12 | 18 | 22 | ||||
| Intermediate-2 | 70 | 38 | 39 | 38 | 31 | 39 | ||||
| High | 57 | 31 | 42 | 41 | 15 | 19 | ||||
| Karyotype | .54 | |||||||||
| Normal | 105/179 | 59 | 59/99 | 60 | 46/80 | 58 | ||||
| Unfavorable | 22/179 | 12 | 14/99 | 14 | 8/80 | 10 | ||||
| Driver mutation distribution | .26 | |||||||||
| JAK2 | 109 | 60 | 66 | 65 | 43 | 54 | ||||
| CALR | 40 | 22 | 17 | 17 | 23 | 29 | ||||
| MPL | 11 | 6 | 6 | 6 | 5 | 6 | ||||
| Triple-negative | 22 | 12 | 13 | 13 | 9 | 11 | ||||
| No. of variants/mutations other than JAK2/CALR/MPL | <.001 | |||||||||
| 0 | 35 | 19 | 0 | 0 | 35 | 44 | ||||
| 1 | 64 | 35 | 30 | 30 | 34 | 43 | ||||
| 2 | 48 | 26 | 39 | 39 | 9 | 11 | ||||
| 3 | 18 | 10 | 17 | 17 | 1 | 1 | ||||
| 4 | 10 | 6 | 9 | 9 | 1 | 1 | ||||
| 5 | 3 | 2 | 3 | 3 | 0 | 0 | ||||
| 6 | 3 | 2 | 3 | 3 | 0 | 0 | ||||
| 11 | 1 | <1 | 1 | 1 | 0 | 0 | ||||